美国总统拟对处方药价格“开刀”：对创新药影响几何，能否落地？

Core Viewpoint - The recent executive order signed by President Trump aims to lower prescription drug prices in the U.S. to align with international pricing, but the feasibility and specific price reductions remain uncertain [1][5][6] Group 1: Drug Pricing and Market Dynamics - The U.S. brand drug prices are over three times higher than those in other countries, despite existing discounts [2] - The U.S. accounts for approximately 75% of global pharmaceutical profits while representing less than 5% of the world's population [2] - The high drug prices in the U.S. are attributed to the healthcare system's labor costs and pricing mechanisms, with profits primarily benefiting domestic pharmaceutical companies and insurance providers [2] Group 2: Impact on Global Pharmaceutical Industry - If the U.S. drug pricing policy is implemented, it could significantly impact the global innovative drug industry [3] - Chinese companies like BeiGene and Junshi Biosciences have successfully launched innovative drugs in the U.S., with prices significantly higher than in China, indicating a potential market shift if U.S. prices are lowered [2][3] Group 3: Uncertainty of Implementation - The executive order's effectiveness is uncertain due to the U.S. legal framework that restricts direct negotiations between the government and pharmaceutical companies [6] - The current system relies on Pharmacy Benefit Managers (PBMs) for drug price negotiations, which complicates the implementation of price reductions [6] - The potential for legal challenges from pharmaceutical companies and insurers could hinder the success of the proposed pricing reforms [6]